Oxbridge Re Holdings Ltd. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oxbridge Re Holdings Limited (the "Company") on March 25, 2024. The filing details the adoption of a new equity incentive plan and the subsequent grant of equity awards to employees and directors of SurancePlus Holdings Ltd. ("SPH"), a wholly owned subsidiary of the Company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance and compensation arrangements.
Material Changes and Equity Grants
On March 25, 2024, the Company and SPH approved the SurancePlus Holdings Ltd. 2024 Equity Incentive Plan. Key terms include:
- Plan Authorization: Up to 750,000 shares of SPH Ordinary Shares are authorized for grants of restricted shares, restricted share units, and options.
- Initial Grants:
- Restricted Shares: An aggregate of 200,000 SPH Ordinary Shares were granted to employees, vesting ratably over 1 year.
- Options: Options to purchase 548,100 SPH Ordinary Shares were granted, vesting quarterly over 4 years with an exercise price of $15.00 per share.
- Executive and Director Awards:
- Jay Madhu (CEO): 125,300 restricted shares and options to purchase 365,400 shares.
- Wrendon Timothy (CFO): 53,700 restricted shares and options to purchase 156,600 shares.
- Non-Employee Directors: Dwight Merren, Arun Gowda, and Lesley Thompson each received 2,000 restricted shares.
Outlook, Risks, and Contingencies
The filing notes that unvested restricted shares and options will immediately vest upon a change of control of SPH. The securities were issued under an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as they were not part of a public offering. The plan is set to terminate on the 10th anniversary of its effective date unless terminated earlier.
Investor Verification Checklist
- Verify the total number of shares authorized under the SPH Equity Incentive Plan (750,000) against the initial grants made (200,000 restricted shares and 548,100 options).
- Confirm the exercise price of $15.00 per share for the options granted and compare it to the current market price of SPH or OXBR shares.
- Review the vesting schedules: 1 year for restricted shares and 4 years (quarterly increments) for options.
- Check the change of control provisions for immediate acceleration of unvested awards.
- Examine the attached exhibits (10.5, 10.6, 10.7) for full legal terms of the plan and award agreements.